Advertisement


Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Advertisement